Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,129.39 -9.87 -0.31%
FTSE 100 6,587.63 3.46 0.05%
DAX 9,304.61 -13.21 -0.14%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Durata Therapeutics to Host Reimbursement Seminar on April 23, 2013



Durata Therapeutics to Host Reimbursement Seminar on April 23, 2013

CHICAGO, April 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced that it will host a reimbursement seminar for
the investment community on Tuesday, April 23, 2013 at the NASDAQ MarketSite
in New York City. The 90-minute seminar will begin at 10:00 a.m. Eastern Time
and will be simultaneously webcast.

The seminar will be conducted by Avalere Health, LLC, a leading advisory
company focused on healthcare business strategy and public policy, with the
goal of providing an overview of the hospital and outpatient reimbursement
landscape and market access in today's evolving healthcare environment.

Attendance at this event is by invitation only and space is limited.
Professional investors and analysts wishing to attend should contact
mricardo@duratatherapeutics.com, by Friday, April 12^th to register.

A live webcast of the presentation can be accessed from the Investor Relations
section of the Company's website at www.duratatherapeutics.com. A replay of
the presentation will also be available on the Durata website.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with ABSSSI caused by susceptible gram-positive
bacteria.

Forward-looking statements

Statements contained in this press release contain forward-looking statements
that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this press release, including
statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management, are forward-looking statements. The words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"
"potential," "will," "would," "could," "should," "continue," and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.

CONTACT: Investor Relations and Public Affairs Contact
         Allison Wey
         Durata Therapeutics, Inc.
         Vice President, Investor Relations and Public Affairs
         (312) 219-7017
         awey@duratatherapeutics.com
        
         Media Relations Contact
         Jed Weiner
         White Oak Communications, Inc.
         (847) 392-4186
         jed.weiner@comcast.net

Durata Therapeutics, Inc. Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement